

# Contents

<b>Author biographies</b>	<b>vii</b>
<b>Abbreviations</b>	<b>ix</b>
<b>Dedication</b>	<b>xiii</b>
<b>1 Introduction</b>	<b>1</b>
Historical perspective	1
Epidemiology	3
Etiology	4
Clinical manifestations	4
Pathophysiology	5
References	7
<b>2 Diagnosis</b>	<b>9</b>
Diagnostic laboratory tests	9
Differential diagnosis	15
Clinical risk scores	16
References	17
<b>3 Monitoring response to treatment</b>	<b>21</b>
Hematological response	21
Cytogenetic response	21
Molecular monitoring methods	23
Rising <i>BCR-ABL</i> levels	26
Pharmacokinetics	28
Monitoring protocol in different clinical settings	28
References	30
<b>4 Management of patients with chronic myeloid leukemia</b>	<b>35</b>
Current approach to treatment	35
Which tyrosine kinase inhibitor to use?	36
Determining the treatment goals	42
Achieving treatment goals	45

Identifying high-risk patients based on early molecular response	46
Risk-adapted therapy	47
Other promising frontline approaches	48
References	49

<b>5 Challenges of treatment: tyrosine kinase inhibitor-resistant chronic myeloid leukemia</b>	<b>53</b>
Mechanisms of resistance	53
Therapeutic options for patients who fail frontline therapy	59
Other tyrosine kinase inhibitors after failure of frontline therapy	60
Allogeneic stem cell transplantation	61
References	62



<http://www.springer.com/978-3-319-08349-0>

Handbook of Chronic Myeloid Leukemia

Hughes, T.P.; Ross, D.M.; Melo, J.V.

2014, XIII, 65 p. 14 illus., 12 illus. in color., Softcover

ISBN: 978-3-319-08349-0